BioCryst Pharma (BCRX) Tops Q3 EPS by 8c

BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.12), $0.08 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $2.11 million.

Cash, cash equivalents and investments totaled $127.6 million at September 30, 2014, compared to $40.8 million at December 31, 2013. This significant increase in cash and investments resulted from the Company's successful June public offering of common stock.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Movano (MOVE) Misses Q2 EPS by 195c